Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Doxazosin Mesylate

FDA-approved product (tablet, oral), marketed as Cardura, Cardura Xl, Doxazosin Mesylate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Doxazosin Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia
  • Hypertension
  • Myocardial infarction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli58.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Doxazosin Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Doxazosin Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treating Nightmares in Posttraumatic Stress Disorder With Clonidine and Doxazosin

    NCT05360953 · start 2022-06-17

    Registered record
    Registry ID
    NCT05360953
    Conditions
    Posttraumatic Stress Disorder
    Interventions
    Clonidine; Doxazosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Suspended
    Start
    2022-06-17
    Completion
    2026-07-31
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPosttraumatic Stress Disorder
    InterventionClonidine; Doxazosin; Placebo
    PhasePhase 2
    Registry statusSuspended

  • Intermittent Catheterization Versus Trial Without Catheter

    NCT05094947 · start 2021-08-03

    Registered record
    Registry ID
    NCT05094947
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    intermittent catheterization; trial without catheter; alpha-blockers
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-08-03
    Completion
    2022-05
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    Interventionintermittent catheterization; trial without catheter; alpha-blockers
    PhaseNot applicable
    Registry statusUnknown

  • Hyperintense: Midlife Hypertension and the Brain

    NCT06175663 · start 2021-07-06

    Registered record
    Registry ID
    NCT06175663
    Conditions
    Hypertension; Small Vessel Cerebrovascular Disease
    Interventions
    Antihypertensive medication withdrawal
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-07-06
    Completion
    2023-12-31
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Small Vessel Cerebrovascular Disease
    InterventionAntihypertensive medication withdrawal
    PhaseNot recorded
    Registry statusUnknown

  • Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Primary Aldosteronism

    NCT04991961 · start 2020-09-15

    Registered record
    Registry ID
    NCT04991961
    Conditions
    Hypertension; Primary Aldosteronism
    Interventions
    withdraw antihypertensive drugs
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-09-15
    Completion
    2024-10-31
    Enrolment
    341

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Primary Aldosteronism
    Interventionwithdraw antihypertensive drugs
    PhaseNot recorded
    Registry statusCompleted

  • Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection - Systematic Review and Meta-analysis

    NCT04557072 · start 2020-08-01

    Registered record
    Registry ID
    NCT04557072
    Conditions
    Pheochromocytoma
    Interventions
    Selective alpha-1-antagonist; Non-selective alpha-1-antagonist
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-08-01
    Completion
    2020-11-02
    Enrolment
    1,344

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPheochromocytoma
    InterventionSelective alpha-1-antagonist; Non-selective alpha-1-antagonist
    PhaseNot recorded
    Registry statusCompleted

  • Influence of the Autonomic Nervous System in Response to Exercise in Hypertensive Individuals

    NCT04371757 · start 2020-04-30

    Registered record
    Registry ID
    NCT04371757
    Conditions
    Autonomic Nervous System; Hypertension
    Interventions
    α1-adrenergic block; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-04-30
    Completion
    2021-12-23
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutonomic Nervous System; Hypertension
    Interventionα1-adrenergic block; Placebo
    PhaseNot applicable
    Registry statusUnknown

  • A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD

    NCT03339258 · start 2018-04-15

    Registered record
    Registry ID
    NCT03339258
    Conditions
    Stress Disorders, Post-Traumatic
    Interventions
    Doxazosin Mesylate, Extended Release; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-04-15
    Completion
    2024-06
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStress Disorders, Post-Traumatic
    InterventionDoxazosin Mesylate, Extended Release; Placebo
    PhasePhase 2
    Registry statusUnknown

  • Testing Doxazosin to Treat Stress Mechanisms in Alcoholism

    NCT02989493 · start 2017-04-12

    Registered record
    Registry ID
    NCT02989493
    Conditions
    Alcoholism
    Interventions
    Doxazosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-04-12
    Completion
    2020-03-13
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcoholism
    InterventionDoxazosin; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of Doxazosin to Alter the Abuse of Oxycodone

    NCT03415581 · start 2017-02-12

    Registered record
    Registry ID
    NCT03415581
    Conditions
    Opioid-use Disorder
    Interventions
    Intranasal Oxycodone; Cue Session
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-02-12
    Completion
    2019-12-23
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-use Disorder
    InterventionIntranasal Oxycodone; Cue Session
    PhasePhase 2
    Registry statusTerminated

  • CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders

    NCT02500602 · start 2016-06-01

    Registered record
    Registry ID
    NCT02500602
    Conditions
    Posttraumatic Stress Disorder; Alcohol Use Disorders
    Interventions
    doxazosin; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-06-01
    Completion
    2019-12-16
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPosttraumatic Stress Disorder; Alcohol Use Disorders
    Interventiondoxazosin; placebo
    PhasePhase 2
    Registry statusCompleted

  • Complementary Combination Therapy for Cocaine Dependence

    NCT02538744 · start 2015-08

    Registered record
    Registry ID
    NCT02538744
    Conditions
    Cocaine Dependence
    Interventions
    Doxazosin; Modafinil; cocaine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-08
    Completion
    2018-08-21
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine Dependence
    InterventionDoxazosin; Modafinil; cocaine; Placebo
    PhasePhase 1
    Registry statusCompleted

  • A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD

    NCT01959022 · start 2013-10

    Registered record
    Registry ID
    NCT01959022
    Conditions
    Stress Disorders, Post-Traumatic
    Interventions
    Doxazosin XL
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-10
    Completion
    2016-06
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStress Disorders, Post-Traumatic
    InterventionDoxazosin XL
    PhasePhase 4
    Registry statusCompleted

  • The Changes of Urine Growth Factors Level

    NCT06282731 · start 2013-05-31

    Registered record
    Registry ID
    NCT06282731
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Silodosin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2013-05-31
    Completion
    2017-04-27
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionSilodosin
    PhaseEarly phase 1
    Registry statusCompleted

  • Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?

    NCT01730846 · start 2013-02

    Registered record
    Registry ID
    NCT01730846
    Conditions
    Smoking
    Interventions
    Doxazosin 4mg/day; Placebo; Doxazosin 8mg/day
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-02
    Completion
    2016-11
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmoking
    InterventionDoxazosin 4mg/day; Placebo; Doxazosin 8mg/day
    PhasePhase 2
    Registry statusCompleted

  • Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1

    NCT01661621 · start 2012-08

    Registered record
    Registry ID
    NCT01661621
    Conditions
    Bladder Outlet Obstruction
    Interventions
    Detrusitol 4 mg QD; Doxazosin 4 mg QD
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-08
    Completion
    2013-08
    Enrolment
    395

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBladder Outlet Obstruction
    InterventionDetrusitol 4 mg QD; Doxazosin 4 mg QD
    PhasePhase 4
    Registry statusCompleted